Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company is headquartered in Nashville, Tennessee and currently employs 91 full-time employees. The company went IPO on 2009-08-11. The firm is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for CPIX. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: CPIX is a Sell candidate.
CPIX stock price ended at $3.91 on 金曜日, after rising 8.91%
On the latest trading day Feb 06, 2026, the stock price of CPIX rose by 8.91%, climbing from $3.54 to $3.91. Throughout the session, the stock experienced a volatility of 12.43%, with prices fluctuating between a daily low of $3.54 and a high of $3.98. Alongside this price increase, trading volume also rose by 91.3K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 102.7K shares were traded, amounting to a market value of approximately $58.4M.